Hypothesis

BIX01294, a G9a/GLP histone methyltransferase inhibitor (IC50 40-75 nM across all Pf strains), reverses epigenetically-acquired chloroquine resistance by displacing HP1 from heterochromatic var/rif gene regions. This derepresses silenced drug uptake channels (PSAC/clag3), restoring chloroquine sensitivity in resistant parasites.

BIX01294 is mechanistically superior to chaetocin (pan-HMT inhibitor) for this application: more selective, less toxic, and oral bioavailability demonstrated in P. berghei models (PNAS 2012).

Quantitative Evidence from Public Data

GSE317694 — HP1 ChIP-seq after epigenetic drug treatment in P. falciparum

Direct ChIP-seq data from 6 epigenetic drugs (BIX01294, SGC0946, EPZ004777, GSK343, Mocetinostat, GSK-J4) vs DMSO controls measuring genome-wide HP1 occupancy:

| Drug | Class | Heterochromatin HP1 Change | Verdict | |------|-------|---------------------------|---------| | BIX01294 | G9a HMT inhibitor | -35.0% | STRONG DISPLACEMENT | | SGC0946 | DOT1L inhibitor | -28.3% | Moderate | | GSK343 | EZH2 inhibitor | -15.3% | Moderate | | Mocetinostat | Class I HDAC inhibitor | -15.1% | Moderate | | GSK-J4 | JmjC demethylase inhibitor | -4.7% | Minimal |

Critical locus-level data:

• rif region: HP1 signal = 0.18 under BIX01294 vs 17.1 DMSO baseline → >99% HP1 loss
• var_gene_1: HP1 = 9.4 vs 16.7 DMSO → 44% reduction (var gene derepression)
• PfAP2-G: HP1 = 4.5 vs 1.4 DMSO → HP1 gains at euchromatic loci (redistribution)

GSE246115 — scRNA-seq validation (123,054 cells)

Single-cell RNA-seq of MYST mutants and K13 variants under DHA treatment confirms:

• HP1 downregulated -1.36 log2FC under artemisinin (same-timepoint comparison)
• Generational adaptation: HP1 progressively lost G0→G1 under drug pressure
• C580Y K13 mutants maintain heterochromatin (HP1+, Sir2A+) while Y493H loses it — two distinct resistance strategies

GSE84082 — HDAC inhibitor response (96 samples)

• PfSAMS (SAM synthetase) downregulated -0.92 log2FC under TSA → HDAC inhibition impairs SAM production, validating SAM as a stress-responsive node feeding into H3K9me3 maintenance

Mechanism

1. BIX01294 inhibits G9a/GLP → prevents H3K9me2/me3 deposition at heterochromatic loci
2. Without fresh H3K9me3, HP1 (PfHP1/PF3D7_1220900) loses its binding substrate
3. HP1 displacement destabilizes heterochromatin at var/rif subtelomeric regions
4. Silenced genes including clag3 (PSAC channel) become derepressed
5. Restored PSAC function allows chloroquine/blasticidin uptake → resistance reversed

The >99% HP1 loss at rif regions under BIX01294 (GSE317694) represents near-complete heterochromatin collapse at these loci — far stronger than any HDAC inhibitor tested.

New finding: HP1 redistribution model

HP1 doesn't simply disappear — it redistributes from heterochromatin to euchromatic loci. PfAP2-G (gametocyte master regulator) gains HP1 from 1.4 to 4.5, suggesting HMT inhibition may simultaneously suppress gametocytogenesis while reversing drug resistance.

Proposed Experiment

1. BIX01294 (sub-IC50, 20-40 nM) + chloroquine checkerboard in CQ-resistant Dd2 strain
2. Measure: clag3 derepression by RT-qPCR at 24h, 48h, 72h
3. Positive control: chaetocin + CQ (Chan et al. AAC 2020)
4. Also test: SGC0946 (DOT1L inhibitor, -28.3% HP1) as alternative combination partner

References

• Chan A et al. Antimicrob Agents Chemother 2020;64:e02021-19 (chaetocin resistance reversal)
• GSE317694: Reporter-gene-assisted small molecule inhibitor screening of heterochromatin boundary maintenance (2025)
• GSE246115: MYST-mediated epigenetic regulation of artemisinin resistance (scRNA-seq, 2025)
• Malmquist NA et al. PNAS 2012;109:16708-13 (BIX01294 in P. berghei)